Piper Sandler Reaffirms Their Buy Rating on NovoCure (NVCR)
Piper Sandler analyst Jason Bednar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $28.00.
NovoCure’s Growth Potential Boosted by FDA Approval and Market Expansion
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...
Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune’s Market Potential
Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target ...
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...
FierceBiotech2d
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer—which the company described as the first treatment ...
Seeking Alpha2d
NovoCure: There Is Still More Upside
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment, which resulted in positive price action. The lung cancer market will significantly increase NovoCure's scale ...
Yahoo Finance2d
Novocure shares soar 33% as FDA approves lung cancer treatment
Investing.com -- Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer.
Nasdaq3d
NovoCure Breaks Above 200-Day Moving Average - Bullish for NVCR
In trading on Tuesday, shares of NovoCure Ltd (Symbol: NVCR) crossed above their 200 day moving average of $16.73, changing hands as high as $19.33 per share. NovoCure Ltd shares are currently ...
Yahoo Finance2d
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
NovoCure (NVCR) shares ended the last trading session 10.7% higher at $17.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.
STAT3d
A controversial approval for Novocure’s device
From my colleague Adam Feuerstein: The FDA yesterday expanded the approval of Novocure’s Optune electrical field medical device to include the treatment of metastatic non-small cell lung cancer.
Yahoo Finance2d
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC ...